CAN-508

CAN-508 is a small molecule experimental drug and research tool that acts as a selective inhibitor of cyclin-dependent kinase 2 (CDK2). Chemically identified as a purine derivative with the formula C9H10N6O, it targets the ATP-binding site of CDK2, a serine/threonine-protein kinase essential for the G1/S phase transition in the eukaryotic cell cycle. By inhibiting CDK2 activity, CAN-508 induces cell cycle arrest and prevents the proliferation of various cancer cell lines. It was primarily developed and characterized within academic research settings, notably at Palacký University, to explore the therapeutic potential of CDK inhibition in oncology. While it remains in the preclinical stage, it is widely utilized in laboratory studies as a tool compound to investigate cell cycle regulation and signaling pathways.

Other names

4-[(2,6-diamino-9H-purin-9-yl)methyl]phenolCAS 140651-18-9CAS140651-18-9CAS-140651-18-9